BR112022017102A2 - Métodos para tratar esclerose múltipla progressiva primária (ppms), retardar a progressão de ppms, retardar o início de pelo menos um evento de progressão em um indivíduo com ppms, reduzir o risco de um indivíduo com ppms ter pelo menos um evento de progressão e reduzir a deficiência em um indivíduo com ppms e compostos - Google Patents
Métodos para tratar esclerose múltipla progressiva primária (ppms), retardar a progressão de ppms, retardar o início de pelo menos um evento de progressão em um indivíduo com ppms, reduzir o risco de um indivíduo com ppms ter pelo menos um evento de progressão e reduzir a deficiência em um indivíduo com ppms e compostosInfo
- Publication number
- BR112022017102A2 BR112022017102A2 BR112022017102A BR112022017102A BR112022017102A2 BR 112022017102 A2 BR112022017102 A2 BR 112022017102A2 BR 112022017102 A BR112022017102 A BR 112022017102A BR 112022017102 A BR112022017102 A BR 112022017102A BR 112022017102 A2 BR112022017102 A2 BR 112022017102A2
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- progression
- ppms
- delay
- reduce
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Abstract
MÉTODOS PARA TRATAR ESCLEROSE MÚLTIPLA PROGRESSIVA PRIMÁRIA (PPMS), RETARDAR A PROGRESSÃO DE PPMS, RETARDAR O INÍCIO DE PELO MENOS UM EVENTO DE PROGRESSÃO EM UM INDIVÍDUO COM PPMS, REDUZIR O RISCO DE UM INDIVÍDUO COM PPMS TER PELO MENOS UM EVENTO DE PROGRESSÃO E REDUZIR A DEFICIÊNCIA EM UM INDIVÍDUO COM PPMS E COMPOSTOS. São fornecidos neste documento métodos para tratar a Esclerose Múltipla Progressiva Primária (PPMS) em um indivíduo em necessidade dos mesmos, administrando ao indivíduo cerca de 200 mg de fenebrutinibe duas vezes ao dia, ou uma quantidade equivalente de um sal farmaceuticamente aceitável do mesmo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062982872P | 2020-02-28 | 2020-02-28 | |
US202063051756P | 2020-07-14 | 2020-07-14 | |
PCT/US2021/019502 WO2021173740A1 (en) | 2020-02-28 | 2021-02-25 | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022017102A2 true BR112022017102A2 (pt) | 2022-11-16 |
Family
ID=74885089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022017102A BR112022017102A2 (pt) | 2020-02-28 | 2021-02-25 | Métodos para tratar esclerose múltipla progressiva primária (ppms), retardar a progressão de ppms, retardar o início de pelo menos um evento de progressão em um indivíduo com ppms, reduzir o risco de um indivíduo com ppms ter pelo menos um evento de progressão e reduzir a deficiência em um indivíduo com ppms e compostos |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230091561A1 (pt) |
EP (1) | EP4110339A1 (pt) |
JP (1) | JP2023515528A (pt) |
KR (1) | KR20220148826A (pt) |
CN (1) | CN115175682A (pt) |
AU (1) | AU2021227674A1 (pt) |
BR (1) | BR112022017102A2 (pt) |
CA (1) | CA3170685A1 (pt) |
CL (1) | CL2022002317A1 (pt) |
IL (1) | IL295476A (pt) |
MX (1) | MX2022010513A (pt) |
TW (1) | TW202146022A (pt) |
WO (1) | WO2021173740A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
IL300209A (en) | 2016-02-29 | 2023-03-01 | Hoffmann La Roche | Dosage preparations containing Bruton's tyrosine kinase inhibitor |
-
2021
- 2021-02-25 BR BR112022017102A patent/BR112022017102A2/pt unknown
- 2021-02-25 MX MX2022010513A patent/MX2022010513A/es unknown
- 2021-02-25 CN CN202180017387.XA patent/CN115175682A/zh active Pending
- 2021-02-25 AU AU2021227674A patent/AU2021227674A1/en active Pending
- 2021-02-25 JP JP2022550934A patent/JP2023515528A/ja active Pending
- 2021-02-25 WO PCT/US2021/019502 patent/WO2021173740A1/en unknown
- 2021-02-25 TW TW110106714A patent/TW202146022A/zh unknown
- 2021-02-25 EP EP21712677.0A patent/EP4110339A1/en active Pending
- 2021-02-25 IL IL295476A patent/IL295476A/en unknown
- 2021-02-25 KR KR1020227030440A patent/KR20220148826A/ko unknown
- 2021-02-25 CA CA3170685A patent/CA3170685A1/en active Pending
- 2021-02-25 US US17/905,121 patent/US20230091561A1/en active Pending
-
2022
- 2022-08-24 CL CL2022002317A patent/CL2022002317A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021173740A1 (en) | 2021-09-02 |
JP2023515528A (ja) | 2023-04-13 |
KR20220148826A (ko) | 2022-11-07 |
EP4110339A1 (en) | 2023-01-04 |
IL295476A (en) | 2022-10-01 |
CA3170685A1 (en) | 2021-09-02 |
MX2022010513A (es) | 2022-09-21 |
CL2022002317A1 (es) | 2023-03-03 |
CN115175682A (zh) | 2022-10-11 |
US20230091561A1 (en) | 2023-03-23 |
TW202146022A (zh) | 2021-12-16 |
AU2021227674A1 (en) | 2022-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021005011A (es) | Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7). | |
MX2021014177A (es) | Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos. | |
ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
BR112022004474A8 (pt) | Método de tratamento ou prevenção de um câncer em um sujeito, molécula de ligação ao antígeno para uso neste e uso desta | |
BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
EA202090510A1 (ru) | Способ лечения бокового амиотрофического склероза придопидином | |
EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
EA202190749A1 (ru) | Способы комбинированной терапии | |
MX2020014303A (es) | Inhibición de la proteína de union a creb (cbp). | |
EP4279127A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
BR112022005757A2 (pt) | Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma | |
BR112022000231A2 (pt) | Novos métodos | |
MX2022010258A (es) | Composiciones y métodos para tratar la lesión renal. | |
BR112022017102A2 (pt) | Métodos para tratar esclerose múltipla progressiva primária (ppms), retardar a progressão de ppms, retardar o início de pelo menos um evento de progressão em um indivíduo com ppms, reduzir o risco de um indivíduo com ppms ter pelo menos um evento de progressão e reduzir a deficiência em um indivíduo com ppms e compostos | |
BR112022026186A2 (pt) | Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras | |
BR112022025946A2 (pt) | Composto, composição farmacêutica e método de tratamento de uma doença | |
MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
MX2022012310A (es) | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. | |
BR112021024835A2 (pt) | Tratamento para sinuclenopatias | |
MX2022012632A (es) | Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington. | |
BR112021010856A2 (pt) | Vibegron para o tratamento de sintomas de bexiga hiperativa | |
MX2021011253A (es) | Moduladores de tdp-43. | |
EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
MX2021005189A (es) | Uso de tivozanib para tratar sujetos con cancer refractario. |